相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。IL-21 induces in vivo immune activation of NK cells and CD8+ T cells in patients with metastatic melanoma and renal cell carcinoma
Klaus Stensgaard Frederiksen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Biochemotherapy for the treatment of metastatic malignant melanoma: A systematic review
Caroline Hamm et al.
CANCER TREATMENT REVIEWS (2008)
Dendritic cell vaccines in melanoma: From promise to proof?
W. J. Lesterhuis et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2008)
The role of vaccine therapy in the treatment of melanoma
Marko Lens
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma
John A. Thompson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 study group
Alessandro Testori et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III Trial Comparing Concurrent Biochemotherapy With Cisplatin, Vinblastine, Dacarbazine, Interleukin-2, and Interferon Alfa-2b With Cisplatin, Vinblastine, and Dacarbazine Alone in Patients With Metastatic Malignant Melanoma (E3695): A Trial Coordinated by the Eastern Cooperative Oncology Group
Michael B. Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy
Khoi Q. Tran et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanoma
Reinhard Dummer et al.
MOLECULAR THERAPY (2008)
Treatment of metastatic melanoma with autologous CD4+T cells against NY-ESO-1
Naomi N. Hunder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines
Cornelis J. M. Melief et al.
NATURE REVIEWS CANCER (2008)
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma:: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG)
K. Spieth et al.
ANNALS OF ONCOLOGY (2008)
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
Steven A. Rosenberg et al.
NATURE REVIEWS CANCER (2008)
Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: A meta-analysis of 18 trials involving 2,621 patients
Natalie J. Ives et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Interleukin-21 signaling: Functions in cancer and autoimmunity
Ian D. Davis et al.
CLINICAL CANCER RESEARCH (2007)
Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
Stephanie G. Downey et al.
CLINICAL CANCER RESEARCH (2007)
The role of the CTLA4 blockade in the treatment of malignant melanoma
Lee D. Cranmer et al.
CANCER INVESTIGATION (2007)
Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb
Betty Li et al.
CLINICAL IMMUNOLOGY (2007)
Mechanisms involved in synergistic anticancer immunity of Anti-4-1BB and Anti-CD4 therapy
Beom K. Choi et al.
CANCER RESEARCH (2007)
Single-agent interleukin-2 in the treatment of metastatic melanoma: A systematic review
Teresa Petrella et al.
CANCER TREATMENT REVIEWS (2007)
Intratumoral injection of IL-12 plasmid DNA - results of a phase I/IB clinical trial
D. M. Mahvi et al.
CANCER GENE THERAPY (2007)
Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events
Jeffrey Weber
ONCOLOGIST (2007)
Tremelimumab (CP-675,206), a cytotoxic T lymphocyte-associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer
Antoni Ribas et al.
ONCOLOGIST (2007)
More than one reason to rethink the use of peptides in vaccine design
Anthony W. Purcell et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer stage IV melanoma: Results of the EORTC 18951 Biochemotherapy Trial
Henrik Schmidt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Immunostimulatory monoclonal antibodies for cancer therapy
Ignacio Melero et al.
NATURE REVIEWS CANCER (2007)
Costimulation, coinhibition and cancer
Brant A. Inman et al.
CURRENT CANCER DRUG TARGETS (2007)
Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy
Ahmad A. Tarhini et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion
Daniel J. Powell et al.
JOURNAL OF IMMUNOLOGY (2006)
Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma
Andreas Mackensen et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan et al.
SCIENCE (2006)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Adoptive immunotherapy for cancer: building on success
L Gattinoni et al.
NATURE REVIEWS IMMUNOLOGY (2006)
Allogeneic and autologous melanoma vaccines:: Where have we been and where are we going?
VK Sondak et al.
CLINICAL CANCER RESEARCH (2006)
Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma:: a randomized phase III trial of the DC study group of the DeCOG
D Schadendorf et al.
ANNALS OF ONCOLOGY (2006)
Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma
E Bajetta et al.
ANNALS OF ONCOLOGY (2006)
Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma
R Dummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: A randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group
R Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group
U Keilholz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
P Attia et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model
H Schmidt et al.
BRITISH JOURNAL OF CANCER (2005)
Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-α in patients with advanced melanoma
MS Vuoristo et al.
MELANOMA RESEARCH (2005)
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma
ME Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: Clinical efficacy
L Heinzerling et al.
HUMAN GENE THERAPY (2005)
Medical progress - Management of cutaneous melanoma
H Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Cancer immunotherapy: moving beyond current vaccines
SA Rosenberg et al.
NATURE MEDICINE (2004)
CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo
M Trikha et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes:: Clinical and immunologic findings
F Belli et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a phase III randomized trial
O Eton et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Interleukin-2 and interleukin-15: immunotherapy for cancer
TA Fehniger et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alfa-2b in advanced melanoma outpatients: Results from an Italian Multicenter phase III Randomized Clinical Trial
R Ridolfi et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Combination chemotherapy with or without s.c. IL-2 and IFN-α:: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM)
J Atzpodien et al.
BRITISH JOURNAL OF CANCER (2002)
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma
SS Agarwala et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3
PG Coulie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
CM Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma
GQ Phan et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma:: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)
A Hauschild et al.
BRITISH JOURNAL OF CANCER (2001)
分享论文
